C eates a Scaled Medical Lase Platfo m, Accele ati g IPG’s St ategic Expa sio i Adva ced Solutio s
Expected to Be Acc etive to G oss Ma gi , EBITDA, a d Adjusted EPS
MARLBOROUGH, Mass., July 16, 2026 (GLOBE NEWSWIRE) — IPG Photo ics Co po atio (NASDAQ: IPGP) today a ou ced that it has e te ed i to a bi di g offe to acqui e Lumibi d Medical. The acquisitio adva ces IPG’s st ategy, fu the expa di g the Adva ced Solutio s po tfolio i att active medical ma kets. The t a sactio is expected to delive fi a cial be efits by addi g a high-ma gi busi ess that is acc etive to g oss ma gi , EBITDA a d adjusted EPS. IPG believes that the combi ed medical busi esses will c eate a scaled medical lase platfo m fo g owth with compleme ta y established leade ship i ophthalmology a d u ology. The compa y expects that this also adds app oximately $1 billio i add essable ma ket fo Adva ced Solutio s, expa di g lo g-te m value c eatio oppo tu ities that leve age IPG’s capabilities.
IPG i te ds to acqui e Lumibi d Medical fo a pu chase p ice of €300 millio o a cash-f ee, debt-f ee basis. The pu chase p ice will be paid i cash at closi g. A co ti ge t ea out co side atio of up to €50 millio additio al i cash is based o achievi g ce tai 2026 a d 2027 pe fo ma ce met ics. The acquisitio will be fu ded with cash o ha d.
“We expect that this acquisitio will accele ate ou st ategic expa sio i att active medical ma kets i Adva ced Solutio s,” said D . Ma k Giti , IPG Photo ics’ Chief Executive Office . “Lumibi d Medical’s leade ship i ophthalmology compleme ts ou st e gth i u ology, which will c eate a scaled medical platfo m with oppo tu ities to accele ate i ovatio , b oade ou comme cial each a d delive diffe e tiated solutio s fo physicia s a d patie ts. We expect the t a sactio to st e gthe ou lo g-te m g owth p ofile a d p ovide sig ifica t value c eatio . I am looki g fo wa d to welcomi g the Lumibi d Medical team to IPG.”
“I’m excited about the futu e of Lumibi d Medical, which will be efit sig ifica tly f om IPG’s scale a d leade ship i lase s, photo ics a d applicatio s,” said Jea -Ma c Ge d e, CEO of Lumibi d Medical. “I am co vi ced that becomi g pa t of IPG will p ovide ou teams, ou tech ologies a d ou custome s with outsta di g oppo tu ities to accele ate this ema kable jou ey while p ese vi g the cultu e of i ovatio that has made ou success.”
Lumibi d Medical is a global leade i diag ostic a d t eatme t systems fo ophthalmology, a highly egulated medical lase ma ket that is la gely d ive by o -disc etio a y spe di g. The compa y desig s a d p oduces diag ostic a d the apeutic tools fo co ditio s i cludi g cata acts, glaucoma, d y eye a d age- elated macula dege e atio , a d is a pa t e of choice fo specialist a d ge e alist patie t ca e. Its p op ieta y lase tech ology delive s i ovative solutio s, f om diag osis to lase t eatme t, th ough ma ket-leadi g b a ds i cludi g Qua tel Medical, Ellex a d Optotek Medical. Headqua te ed i F a ce, the compa y has th ee majo global facilities a d mo e tha 450 employees wo ldwide. Lumibi d Medical has a t ack eco d of sales g owth a d EBITDA ma gi expa sio . Fo the fiscal yea e ded Decembe 31, 2025, Lumibi d Medical epo ted eve ue of €112.2 millio a d EBITDA of €24.1 millio with EBITDA ma gi of 21.5%1.
Followi g completio of the i fo matio a d co sultatio p ocess with Lumibi d Medical’s wo ks cou cil i acco da ce with F e ch law, the pa ties expect to e te i to a defi itive pu chase ag eeme t. IPG Photo ics expects the t a sactio to close du i g the fou th qua te of 2026, subject to customa y closi g co ditio s.
The Compa y will hold a co fe e ce call tomo ow, July 17, 2026, at 8:00 a.m. ET. To access the call, please dial 877-407-6184 i the US o 201-389-0877 i te atio ally. A live webcast of the call will also be available a d a chived o the i vesto elatio s sectio of the Compa y’s website at i vesto .ipgphoto ics.com.
Euge e FedotoffSe io Di ecto , I vesto Relatio sIPG Photo ics Co po atio 508-597-4713efedotoff@ipgphoto ics.com
I ovatio is at the hea t of IPG Photo ics. As a global leade i lase tech ology, we apply light to t a sfo m the wo ld. F om ma ufactu i g to medical a d beyo d, ou b eakth ough lase solutio s powe ou custome s’ success a d expa d what’s possible. Discove mo e at www.ipgphoto ics.com.
I fo matio a d stateme ts p ovided by IPG a d its employees, i cludi g stateme ts i this p ess elease, that elate to futu e pla s, eve ts o pe fo ma ce a e fo wa d-looki g stateme ts withi the mea i g of the fede al secu ities laws, i cludi g the P ivate Secu ities Litigatio Refo m Act of 1995, Sectio 27A of the Secu ities Act of 1933 a d Sectio 21E of the Secu ities Excha ge Act of 1934, each as ame ded. These stateme ts i volve isks a d u ce tai ties. A y stateme ts i this p ess elease that a e ot stateme ts of histo ical fact a e fo wa d-looki g stateme ts, i cludi g those stateme ts elated to the p oposed acquisitio of Lumibi d Medical (the “P oposed T a sactio “) a d the timi g a d completio the eof, adva ci g IPG’s st ategy , fu the expa di g the Adva ced Solutio s po tfolio i att active medical ma kets, delive i g fi a cial be efits by addi g a high-ma gi busi ess, acc etive to g oss ma gi , EBITDA a d adjusted EPS, the combi atio c eati g a scaled platfo m fo g owth, addi g app oximately $1 billio i add essable ma ket, expa di g lo g-te m value c eatio oppo tu ities that leve age IPG’s capabilities, expecti g the t a sactio to p ovide oppo tu ities to accele ate i ovatio , b oade comme cial each, delive diffe e tiated solutio s, to st e gthe lo g-te m g owth p ofile, p ovide value c eatio a d to be acc etive to ma gi , EBITDA a d adjusted EPS, the ability to complete the i fo matio a d co sultatio p ocess with Lumibi d Medical’s wo ks cou cil, the executio of defi itive ag eeme ts elati g to the P oposed T a sactio , the ability to obtai equi ed egulato y app ovals a d to satisfy othe customa y closi g co ditio s, the ability to successfully i teg ate Lumibi d Medical’s busi ess a d etai its employees, custome s a d dist ibuto s, a d the ealizatio of a ticipated sy e gies a d the expected closi g date. Facto s that could cause actual esults to diffe mate ially i clude isks a d u ce tai ties, i cludi g isks associated with the st e gth o weak ess of busi ess co ditio s i i dust ies a d geog aphic ma kets that IPG se ves, pa ticula ly the effect of dow tu s i the ma kets IPG se ves; u ce tai ties a d adve se cha ges i the ge e al eco omic co ditio s of ma kets; i ability to ma age isks associated with i te atio al custome s a d ope atio s; cha ges i t ade co t ols a d ta iff policies; IPG’s ability to pe et ate ew applicatio s fo fibe lase s a d i c ease ma ket sha e; the ate of accepta ce a d pe et atio of IPG’s p oducts; fo eig cu e cy fluctuatio s; high levels of fixed costs f om IPG’s ve tical i teg atio ; the app op iate ess of IPG’s ma ufactu i g capacity fo the level of dema d; competitive facto s, i cludi g decli i g ave age selli g p ices; the effect of acquisitio s a d i vestme ts; i ve to y w ite-dow s; asset impai me t cha ges; i tellectual p ope ty i f i geme t claims a d litigatio ; i te uptio i supply of key compo e ts; ma ufactu i g isks; gove me t egulatio s a d t ade sa ctio s; a d othe isks ide tified i IPG’s SEC fili gs. The e ca be o assu a ce that the P oposed T a sactio will be co summated o the a ticipated timeli e o at all. Reade s a e e cou aged to efe to the isk facto s desc ibed i IPG’s A ual Repo t o Fo m 10-K (filed with the SEC o Feb ua y 23, 2026) a d IPG’s epo ts filed with the SEC, as applicable. Actual esults, eve ts a d pe fo ma ce may diffe mate ially. Reade s a e cautio ed ot to ely o the fo wa d-looki g stateme ts, which speak o ly as of the date he eof. IPG u de takes o obligatio to update the fo wa d-looki g stateme ts that may be made to eflect eve ts o ci cumsta ces afte the date he eof o to eflect the occu e ce of u a ticipated eve ts.
We efe to ce tai fi a cial measu es that a e ot ecog ized u de U ited States ge e ally accepted accou ti g p i ciples (“GAAP”) a d a e p ovided as suppleme tal i fo matio to e ha ce u de sta di g of the Compa y’s fi a cial pe fo ma ce. Such o -GAAP fi a cial measu es should ot be co side ed supe io to, as a substitute fo o alte ative to, a d should be co side ed i co ju ctio with, the GAAP fi a cial measu e p ese ted by the Compa y.
